Abstract
Liquid biopsy offers an optimal approach for the early detection of lung cancer that is the leading cause of cancer mortality worldwide. Here, we report the results of AssesSment of early-deteCtion basEd oN liquiD biopsy in LUNG cancer (ASCEND-LUNG, NCT04817046), a prospective study designed to develop early detection models for lung cancer based on multi-omics assays including cell-free DNA (cfDNA) methylation, mutation, and tumor proteins.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
